Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era
- 9 May 2013
- journal article
- clinical trial
- Published by Wiley in Clinical Transplantation
- Vol. 27 (4) , E454-E461
Abstract
Antifungal prophylaxis is recommended in high‐risk patients, but risk criteria remain unclear and the predictive value of Model of End‐Stage Liver Disease (MELD) score is unknown. In a retrospective, single‐center analysis of 667 liver transplants, potential risk factors for fungal infection were assessed, including MELD score. Antifungal prophylaxis was administered in 198 patients (29.4%). During follow‐up (mean 43.6 ± 29.6 months), 263 patients (39.4%) developed ≥1 episode of fungal infection, and 187 (28.0%) patients developed a probable or proven invasive fungal infection requiring systemic antifungal treatment. Patients receiving antifungal prophylaxis had a lower incidence of fungal infection (29.8% vs. 43.5% without prophylaxis, p < 0.001) and invasive fungal infection (17.7% vs. 32.4%, p < 0.001). One‐yr patient survival was 91%, 85% and 69%, respectively, in patients with no fungal infection, fungal colonization and treated invasive fungal infection (p < 0.001); graft survival was 88%, 85% and 66% (p < 0.001). Multivariate analysis indicated that MELD score of 20–30 or ≥30 was associated with a 2.0‐fold or 4.3‐fold increase in relative risk of fungal infection, respectively, and a 2.1‐fold or 3.1‐fold increase in relative risk of invasive fungal infection. In conclusion, liver transplant patients with a MELD score ≥20, and particularly patients with a score ≥30, are candidates for antifungal prophylaxis.Keywords
This publication has 22 references indexed in Scilit:
- Clinical Aspects of Invasive Candidiasis in Solid Organ Transplant RecipientsDrugs, 2009
- Antifungal prophylaxis in liver transplant recipientsLiver Transplantation, 2009
- Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Outcomes of antifungal prophylaxis in high‐risk liver transplant recipientsTransplant Infectious Disease, 2009
- Risk factors forEnterobacteriaceaebacteremia after liver transplantationTransplant International, 2008
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Effect of Prophylaxis on Fungal Infection and Costs for High-Risk Liver Transplant RecipientsLiver Transplantation, 2007
- Targeted prophylaxis with amphotericin B lipid complex in liver transplantationLiver Transplantation, 2000
- Randomized Trial of Fluconazole versus Nystatin for the Prophylaxis of Candida Infection following Liver TransplantationThe Journal of Infectious Diseases, 1996
- MAJOR INFECTIOUS COMPLICATIONS AFTER ORTHOTOPIC LIVER TRANSPLANTATION AND COMPARISON OF OUTCOMES IN PATIENTS RECEIVING CYCLOSPORINE OR FK506 AS PRIMARY IMMUNOSUPPRESSIONTransplantation, 1995